Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25355781 | 1.00 | LOX (0.49) | LOXLOXL2ITGA4ITGB7ACACB | |
| SCHEMBL26985727 | 0.81 | ALDH1A1 (0.47) | LOXLOXL2ITGA4ITGB7ACACB | |
| SCHEMBL31407804 | 0.81 | ACE (0.55) | ITGA4ITGB7PPARGITGB1PTPN1 | |
| SCHEMBL14860326 | 0.81 | ACE (0.55) | ITGA4ITGB7PPARGITGB1PTPN1 | |
| SCHEMBL31407461 | 0.81 | ACE (0.55) | ITGA4ITGB7PPARGITGB1PTPN1 | |
| SCHEMBL27127891 | 0.81 | ALDH1A1 (0.47) | LOXLOXL2ITGA4ITGB7ACACB | |
| SCHEMBL25357726 | 0.80 | GABRP (0.54) | PPARG | |
| SCHEMBL25357821 | 0.80 | LOX (0.55) | LOXLOXL2ACACBFFAR1 | |
| SCHEMBL31747001 | 0.80 | LOX (0.55) | LOXLOXL2ACACBFFAR1 | |
| SCHEMBL31688543 | 0.80 | GABRP (0.54) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | claimed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257343-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | LOX 2651/4885LOXL2 3210/4885ITGA4 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.